文献速递妇科

苯并咪唑衍生物BNZ-111对紫杉醇耐药卵巢癌的抗癌作用

Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2024-06-26

本研究在多种人上皮性卵巢癌细胞系及原位和患者来源异种移植模型中评价苯并咪唑衍生物BNZ-111。BNZ-111对化疗敏感和耐药细胞均显示强细胞毒性,诱导凋亡和G2/M期阻滞,体内显著抑制肿瘤生长且对重要器官无明显毒性。与紫杉醇不同,BNZ-111对紫杉醇耐药细胞有效,可能通过绕过MDR1相互作用并调节β-3微管蛋白表达抑制微管动力学。

要点

  • BNZ-111对化疗敏感和耐药上皮性卵巢癌细胞系均显示强细胞毒性。
  • BNZ-111诱导凋亡和G2/M期细胞周期阻滞。
  • BNZ-111在紫杉醇耐药细胞中有效,可能通过绕过MDR1并调节β-3微管蛋白表达。

核心结论

  • BNZ-111具有良好的类药性质,有望成为铂耐药卵巢癌的治疗选择,满足妇科肿瘤学中关键的临床需求。

研究设计与样本

  • 研究用人上皮性卵巢癌细胞系A2780、HeyA8、SKOV3ip1、A2780-CP20、HeyA8-MDR和SKOV3-TR,以BNZ-111处理并评估细胞增殖、凋亡和细胞周期。
  • 体内实验采用原位和患者来源异种移植模型。

主要发现

  • BNZ-111在化疗敏感和化疗耐药上皮性卵巢癌细胞系中均显示强细胞毒性,诱导凋亡和G2/M期细胞周期阻滞。
  • 体内原位和患者来源异种移植模型显示显著肿瘤生长抑制,对重要器官无明显毒性。
  • 与紫杉醇不同,BNZ-111在紫杉醇耐药细胞中有效,可能通过绕过与MDR1的相互作用并调节β-3微管蛋白表达抑制微管动力学。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Ovarian cancer, a leading cause of cancer-related deaths in women, remains a formidable challenge, especially in the context of platinum-resistant disease. This study investigated the potential of the benzimidazole derivative BNZ-111 as a novel treatment strategy for platinum-resistant ovarian cancer. METHODS: The human EOC cell lines A2780, HeyA8, SKOV3ip1, A2780-CP20, HeyA8-MDR, and SKOV3-TR were treated with BNZ-111, and cell proliferation, apoptosis, and cell cycle were assessed. RESULTS: It demonstrated strong cytotoxicity in both chemo-sensitive and chemo-resistant epithelial ovarian cancer cell lines, inducing apoptosis and G2/M cell cycle arrest. In vivo experiments using orthotopic and patient-derived xenograft models showed significant tumor growth inhibition without apparent toxicity to vital organs. Unlike paclitaxel, BNZ-111 proved effective in paclitaxel-resistant cells, potentially by bypassing interaction with MDR1 and modulating β-3 tubulin expression to suppress microtubule dynamics. CONCLUSION: BNZ-111, with favorable drug-like properties, holds promise as a therapeutic option for platinum-resistant ovarian cancer, addressing a critical clinical need in gynecologic oncology.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Koh B, Ryu JY, Noh JJ, et al. Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer. Gynecol Oncol. 2024. PMID: 38936282. doi:10.1016/j.ygyno.2024.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。